Beam’s base editing therapy for sickle cell hits goal in pivotal trial

Coverage, in order

1. 1d ago
   
   BioPharma Dive indie study

   Beam’s base editing therapy for sickle cell hits goal in pivotal trial

   The result represents a scientific milestone and positions Beam to submit a first-of-its-kind FDA application as soon as the end of the year.

Alivewire groups outlets reporting the same story. Each headline links to the outlet that wrote it; nothing is republished here.